Advertisement

Targeting of Antigens to Antigen-Presenting Cells and their Activation: A Requirement for Vaccine Development

  • Anthony C. Allison
  • Noelene E. Byars
Part of the NATO ASI Series book series (NSSA, volume 155)

Abstract

The efficacy of vaccination was illustrated in a dramatic way by the global eradication of smallpox ten years ago. Vaccination has also greatly reduced morbidity and mortality due to yellow fever in Africa and Central America. In the United States vaccination programs have nearly eliminated deaths from diphtheria, measles and mumps as well as paralytic poliomyelitis and the congenital rubella syndrome (Hilleman, 1985).

Keywords

Genital Herpes Follicular Dendritic Cell MURAMYL Dipeptide Congenital Rubella Syndrome Aluminum Phosphate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alber, T., Daopin, S., Wilson, K., Wozniak, J. A., Cook, S. P., and Matthews, B. W., 1987, Contributions of hydrogen bonds of Thrl57 to the thermodynamic stability of phage T4 lysozyme, Nature 330:41.PubMedCrossRefGoogle Scholar
  2. Allison, A. C., 1987, An overview of host defense mechanisms, in: “Immunopharmcology of Infectious Diseases: Vaccine Adjuvants and Mediators of Non-Specific Resistance,” J.A. Majde, Ed., Alan R. Liss Inc., pp. 17–26, New York.Google Scholar
  3. Allison, A. C., 1988, The role of monocytes, macrophages, Langerhans cells and follicular dendritic cells in persistent virus infections, in: “Persistent Virus Infections,” C. Lopez, and H. Margolis, Alan R. Liss Inc. (in press) New York.Google Scholar
  4. Allison, A. C., and Byars, N. E., 1986, An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity, J.Immunol.Methods 95:157.PubMedCrossRefGoogle Scholar
  5. Allison, A. C., and Byars, N. E., 1987, Vaccine technology: developmental strategies and adjuvants for increased efficiency, Biotechnology 5:1041.CrossRefGoogle Scholar
  6. Allison, A. C., Byars, N. E., and Waters, R. V., 1986, Immunologic adjuvants: efficacy and safety considerations, in: “Advances in Carriers and Adjuvants for Veterinary Biologies,” R.M. Nervig, P. M. Gough, M.L. Kaeberle, and C.A. Whetstone, eds., Iowa State University Press, pp. 91–103.Google Scholar
  7. Balfour, B. M., Drexhage, H. A., Kamperdijk, E. W. A., and Hoefsmid, E. C. M., 1981, Antigen-presenting cells, including Langerhans cells, veiled cells and interdigitating cells, Ciba Foundation Symposium 84:281.PubMedGoogle Scholar
  8. Beasley, R. P., and Hwang, L. Y., 1984, Hepatocellular carcinoma and hepatitis B virus, Semin.Liver Pis., 4:1131.Google Scholar
  9. Beasley, R. P., Hwang, L.Y., Lee, G. C., Lan, C. C., Roan, C. H., Hwang, F. Y., and Chen, C. L., 1983, Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine, Lancet ii:1099.CrossRefGoogle Scholar
  10. Berman, P. W., Gregory, T., Crase, P., and Lasky, L. A., 1985, Protection from genital herpes simplex type 2 infection by vaccination with cloned glycoprotein D. Science 227:1490.PubMedCrossRefGoogle Scholar
  11. Bjerke, S., Elg, J., Braathen, L., and Thorsby, E., 1984, Enriched epidermal Langerhans cells are potent antigen-presenting cells for T cells, J.Invest.Dermatol., 83:286.CrossRefGoogle Scholar
  12. Bjorkman, P. J., Saper, M. A., Samragui, B., Bennett, W. S., Strominger, J. L., and Wiley, D. C., 1987, Structure of the human Class I histocompatibility antigen, HLA-A2, Nature 329:506.PubMedCrossRefGoogle Scholar
  13. Braemer, A. C., Allison, A. C., Byars, N. E., Cutting, J. A., Dietrich, D., McRoberts, M., and Penneke, G., 1987, Immunogencicity of a new feline leukemia virus (FeLV) vaccine, “Proceedings of the XIIIth Symposium of the International Association for Comparative Research on Leukemia and Related Diseases,” November, 1987 (in press) Jerusalem.Google Scholar
  14. Byars, N. E., and Allison, A. C., 1987, Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity, Vaccine 5:223.PubMedCrossRefGoogle Scholar
  15. Dowd, P. S., and Heatley, R. v., 1984, The influence of undernutrition on immunity, Clin.Sci., 66:241.PubMedGoogle Scholar
  16. Epstein, M. A., Morgan, A. J., Finerty, S., Rändle, B. J., and Kirkwood, J. K., 1985, Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine, Nature 318:287.PubMedCrossRefGoogle Scholar
  17. Ellouz, F., Adam, A., Ciorbaru, R., and Lederer, E., 1974, Minimal structural requirements for adjuvant activity of bacterial peptiodoglycan derivatives, Biochem.Biophys.Res.Comm., 59:1317.PubMedCrossRefGoogle Scholar
  18. Geczy, A. F., Alexander, K., Bashir, H. V., Edmonds, J. P., Upfold, L., and Sullivan, J., 1983, HLA-B27, Klebsiella and ankylosing spondylitis: biological and chemical studies, Immunol.Rev, 70:23.PubMedCrossRefGoogle Scholar
  19. Hilleman, M. R., 1985, Newer directions in vaccine development and utilization, J.Infect.Pis., 151:407.CrossRefGoogle Scholar
  20. Hogle, J. M., Chow, and Tilman, D. J., 1985, Three-dimensional structure of poliovirus at 2.9A resolution, Science 229:1358.PubMedCrossRefGoogle Scholar
  21. Humphrey, J. H., Grennan, D., and Sundaram, V., 1984, The origin of follicular dendritic cells in the mouse and the mechanism of trapping of immune complexes on them, Eur.J.Immunol., 14:859.PubMedCrossRefGoogle Scholar
  22. Johnson, G. D., Hardie, D.L., Ling, N.R., and MacLennan, I.C.M., 1986, Human follicular dendritic cells (FDC): a study with monoclonal antibodies (MoAb) Clin.Exp.Immunol., 64:205.PubMedGoogle Scholar
  23. Kaminski, M. S., Kitamura, K., Maloney, D. G., Campbell, M. J., and Levy, R., 1986, Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A Study of hybridoma class switch variants, J.Immunol., 136:1123.PubMedGoogle Scholar
  24. Klaus, G. G., Humphrey, J. H., Kunkle, A., and Dongworth, D. W., 1980, The follicular dendritic cell: its role in antigen presentation in the generation of immunological memory. Immunol Rev., 53:3.PubMedCrossRefGoogle Scholar
  25. Knight, S. C., Krejci, J., Malkovsky, M., Colizzi, V., Gautam, A., and Asherson, G. L., 1985, The role of dendritic cells in the initiation of immune responses to contact sensitizers, 1. In vivo exposure to antigen, Cell.Immunol., 94:427.PubMedCrossRefGoogle Scholar
  26. Knight, S. C., Mertin, J., Stackpole, A., and Clarke, J., 1983, Induction of immune responses in vivo with small numbers of veiled (dendritic) cells, Proc.Natl.Acad.Sci.USA 80:6032.PubMedCrossRefGoogle Scholar
  27. Letvin, N. L., Mutthiah, D., King, N. W., Kiotaki, M., Chalifaux, L. V., Schegal, P. K., Desrosiers, R. C., Arthur, L. O., and Allison, A. C., 1987, AIDS-like disease in macaque monkeys induced by SIV: a vaccine trial. Vaccines 87, Gold Spring Harbor Press, pp. 209–213 New York.Google Scholar
  28. Marx, P. A., Pedersen, N. C., Lerche, N. W., Osborn, K. C., Lowenstine, L. J., Lockner, A. A., Maul, D.H., Kwang, H.-S., Kluge, J. D., Zaiss, C. P., Sharpe, V., Spunner, A. P., Allison, A. C., and Gardner, M. B., 1986, Prevention of simian acquired immune deficiency syndrome with a formalin inactivated type D retrovirus vaccine, J.Virol. 60:431.PubMedGoogle Scholar
  29. Porter, R., and Whelan, J., eds., 1986, “Synthetic Peptides as ANtigens,” Ciba Foundation Symposium 119. Wiley, pp. 1–307, New York.Google Scholar
  30. Reynes, M., Aubert, J. P., Cohen, J. H., Audain, J., Tricollet, V., Diebold and J. Kazatchkine, M. D., 1985, Human follicular dendritic cells express CR1, CR2 and CR3 complement receptor antigens, J.Immunol., 135:2687.PubMedGoogle Scholar
  31. Rossmann, M. G., Arnold, E., Erickson, J. W., Frankenberger, E. A., Griffith, J. P., Hecht, H. J., Johnson, J. E., Kramer, G., Luo, M., and Mosser, A. G., 1985, Structure of the common cold virus and functional relationship to other picornaviruses, Nature , 317:145.PubMedCrossRefGoogle Scholar
  32. Schmolka, I. R., 1977, A review of block polymer surfactants, J.Am.Oil Chem.Soc., 54:110.CrossRefGoogle Scholar
  33. Stark, J. M., Matthews, N., and Locke, J., 1980, Immunogenicity of lipid-conjugated antigens, II. Anti-complementary activity and antigen trapping in the spleen, Immunology, 39:353.PubMedGoogle Scholar
  34. Stanberry, L. R., Bernstein, D. I., Burke, R. L., Pachl, C., and Myers, M., 1987, Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes, J.Infect.Pis., 155:914.CrossRefGoogle Scholar
  35. Steplewski, Z., Spira, G., Blasczyc, M., Lübeck, M. D., Radbruch, A., Illges, H., Herlyn, D., Rajewsky, K., and Scharff, M., 1985, Isolation and characterization of anti-monosialoganglioside monoclonal antibody 19–9 class switch variants, Proc.Natl.Acad.Sci.USA., 82:8653.PubMedCrossRefGoogle Scholar
  36. Unanue, E. R., 1984, Antigen-presenting function of the macrophage, Annu.Rev.Immunol., 2:395.PubMedCrossRefGoogle Scholar
  37. Wechsler, D. S. and Konghshavn, P. A. L., 1986, Heat-labile antibodies effect cure of Trypanosoma musculi infection in C57BL/6 mice, J.Immunol., 137:2968.PubMedGoogle Scholar
  38. Wiley, D. C., Wilson, I. A., and Skehel, J. J., 1981, Structural identification of the antibody binding sites of influenza haemogglutinin and their involvement in antigenic variation, Nature, 289:373.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • Anthony C. Allison
    • 1
  • Noelene E. Byars
    • 1
  1. 1.Department of ImmunologyInstitute of Biological Sciences Syntex ResearchPalo AltoUSA

Personalised recommendations